All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
MSCs in pediatric SR-GvHD after allo-HSCT
Results from a multicenter, retrospective study evaluating the efficacy of mesenchymal stromal cells (MSCs) in pediatric patients (aged ≤18 years; N = 102) with steroid-refractory graft-versus-host disease (SR-GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) were recently published in Bone Marrow Transplantation by Echecopar et al.
Key data: The 28-day overall response rate (ORR) was 76.5% (complete response [CR], 30.4%; partial response [PR], 46.1%). Patients receiving <1 × 10⁶ cells/kg per infusion had a 2-year overall survival (OS) of 22.6% compared with 59.8% for patients receiving ≥1 × 10⁶ cells/kg (p < 0.001). The only treatment-related complication was sepsis, an isolated case attributed to batch contamination; the patient recovered fully and responded to MSC therapy.
Key learning: MSC therapy demonstrated high response rates in pediatric SR-GvHD. Prospective studies are required to validate results to help standardize MSC production and administration in pediatric GvHD.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
